Irritable Bowel Syndrome
Conditions
Keywords
IBS, Probiotic, Constipation, Bifidobacterium longum, Lactobacillus paracasei, Lallemand Health Solutions
Brief summary
The purpose of this study is to determine if two different probiotic strains, Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175, are effective in helping subjects manage the symptoms of IBS
Interventions
DIETARY_SUPPLEMENTBifidobacterium longum R0175
DIETARY_SUPPLEMENTLactobacillus paracasei HA-196
OTHERPlacebo
Sponsors
Lallemand Health Solutions
KGK Science Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female aged 18 years and older. * IBS diagnosis according to Rome III criteria and referral to this study by a clinician. That is, recurrent abdominal pain or discomfort (i.e., uncomfortable sensation other than pain) at least 2 days/month in the last 3 months (response to question 1 of the IBS Rome III module questionnaire \> 2) associated with 2 or more of the following: * Improvement with defecation (response to question 4 of the IBS Rome III module questionnaire \> 0); * Onset associated with a change in stool frequency (response to question 5 or 6 of the IBS Rome III module questionnaire \> 0); * Onset associated with a change in stool form (appearance). (response to question 7 or 8 of the IBS Rome III module questionnaire \> 0). * For women, the abdominal pain or discomfort should be experienced during days other than menstrual bleeding (response to question 2 of the IBS Rome III module questionnaire = 0 or 2) * Criterion must be fulfilled for the last 3 months with symptom onset at least 6 months prior to screening (response to question 3 of the IBS Rome III module questionnaire = 1). * A copy of the IBS module is provided in Appendix A: IBS Rome III Module Questionnaire * Participants from the general population who have IBS symptoms, without a previous diagnosis, will be assessed by the Principle Investigator and included in the study if differential diagnosis confirms IBS. The Principle Investigator will confirm the diagnosis of IBS in any potential participants who have a previous diagnosis of IBS. * Subjects experiencing a pain/discomfort frequency of at least 2 days a week during the run-in period. At visit 2, subjects will be asked In the last 2 weeks, how often each week did you have discomfort or pain anywhere in your abdomen? . The answer must be at least 2. * Subjects diagnosed with IBS who have depression may be included * Absence of black color (melena) or blood in stools. * Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits. * Willingness to discontinue consumption of probiotics (e.g. yogurts, with live, active cultures or supplements). * Able to provide informed consent.
Exclusion criteria
* Subjects with a history of suicidal ideation, or current suicidal ideation * Previous history of gastrointestinal surgery (except appendectomy, cholecystectomy, hernia repair, or hemorrhoidectomy). * Other gastrointestinal diseases (except hemorrhoids and uncomplicated diverticula), as assessed by ultrasonography, colonoscopy, or rectoscopy, or history of Clostridium difficile-associated diarrhea. * A family history (immediate family i.e. siblings and parents) of colorectal cancer, inflammatory bowel disease and/or celiac spruce. * Co-existing organic gastrointestinal disease. * Presence of rectal bleeding, recent weight loss (greater than 5 kg in the past month) or iron deficiency anemia. * History of, or current diagnosis of, liver disease, kidney disease, pulmonary disease, cardiovascular disease, pancreatic disease, any cancer. * Presence of immune-compromised conditions such as AIDS, lymphoma or undergoing long-term corticosteroid treatment * Presence or history of neurological disorders, or significant psychiatric illness. * History of, or current diagnosis of, pelvic floor dyssynergia. * Positive drug or alcohol screen or recent history of drug or alcohol abuse (within 3 years of screening). * Milk or soy allergy. * Use of another investigational product within 3 months of the screening visit. The screened participant could be eligible to participate after a washout period. * Positive pregnancy test in women of child-bearing potential. * Pregnant or breast-feeding or planning on becoming pregnant. * Women of child-bearing potential not using effective contraception. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Intrauterine devices * Vasectomy of partner (shown successful as per appropriate follow-up) * Double barrier method (use of physical barrier by both partners) * Use of any antibiotic drug (e.g., neomycin, rifaximin) within 1 month of screening. The screened participant could be eligible to participate after a 1 month washout period. * Use of PPI or H2R antagonist within 1 month of screening. The screened participant could be eligible to participate after a 1 month washout period. * Daily use of non-steroidal anti-inflammatory drugs, cortisone, or other anti-inflammatory drugs 1 month prior to screening. The screened participant could be eligible to participate after a 1 month washout period. * Current use, or use within the past 1 month, of narcotics or other medications for IBS symptom management (e.g. alosetron, tegaserod, lubiprostone, antispasmodics, antidiarrheals, laxatives, antipsychotics, tricyclic anti-depressants, selective serotonin reuptake inhibitors (SSRIs)). Subjects taking a stable dose of anti-depressants for at least 30 days with no plan to change dosage during the trial will be eligible for inclusion in the study. * Regular use of anti-diarrhea medications and laxatives. Occasional use is permitted prior to screening (≤ than once a month); if current use is \>once per month a one month wash out period is needed prior to screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IBS Symptom Severity Score | 8 Weeks | Assessed using IBS Severity Scoring System Questionnaire, Part I. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anxiety and Depression | 8 weeks | Assessed by administering the HADS questionnaire |
| Abdominal Pain Intensity | 8 weeks | Mean weekly score. Assessed using IBS-SSS |
| Severity of straining | 8 weeks | Assessed using IBS daily diary, 5 point ordinal scale |
| Impact of IBS symptoms on Quality of Life | 8 weeks | Assessed by administration of the IBS-QOL Questionnaire |
| Severity of IBS Symptoms | 4 weeks | Assessed by administration of the IBS-SSS questionnaire, difference from baseline to week 4 |
| Bowel Habit Satisfaction | 8 weeks | Assessed by question 3 of the IBS-SSS |
| Stool Consistency | 8 weeks | Assessed using the Bristol Stool Scale included in the IBS Daily Diary |
| Stool Frequency | 8 weeks | Assessed using the IBS Daily Diary |
| IBS Symptom Severity Score by IBS Subtype | 8 weeks | Assessed using IBS Severity Scoring System Questionnaire, Part I. |
| Number of Responders | 8 weeks | A responder is defined as a participant who has at least a 20% improvement in the IBS-SSS severity score after 8 weeks of supplementation |
| Health Status | 8 weeks | Assessed by administration of the SF-36 questionnaire |
| Abdominal pain frequency | 8 weeks | Assessed using IBS Severity Scoring System Questionnaire, Part I(c) |
| Abdominal distension/tightness | 8 weeks | Assessed using the IBS-SSS Question 2(b) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Microbiome Composition | 8 weeks | Detected in fecal samples |
| Cysteine and serine-protease activity | 8 weeks | Measured in stool samples |
| Amount of rescue medication used throughout the trial | 8 weeks | Use of rescue medication (Bisacodyl 5mg tablet) |
| Safety Anthropometric Measurements | 8 weeks | Blood pressure, Heart rate, Weight and BMI |
| Safety blood parameters | 8 weeks | Complete blood count, electrolytes, markers of kidney and liver function |
| Number of Adverse Events occurring throughout the trial | 8 weeks | — |
| Compliance and Recovery of Probiotic strains | 8 weeks | Monitored by qPCR of fecal samples |
Countries
Canada
Outcome results
None listed